NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading PLYX? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →QuarterlyIQ Insights · PLYX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure. On May 28, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is furnished herewith as Exhibit 99.1. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filing…
Entry into a Material Definitive Agreement. On May 27, 2026, Polaryx Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with approximately 35 investors, including existing investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement a total of 2,502,696 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Private Placement”), representing a…
The Shares will be issued without prior registration in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation S thereunder. In connection with the Purchasers’ execution of the Purchase Agreement, the Purchasers represented to the Company that the Shares to be purchased by them will be acquired solely for their own account and not with a view to or for distributing or reselling such Shares o…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
